Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz gGmbH, Mainz, Germany.
Nat Cancer. 2023 Jul;4(7):937-954. doi: 10.1038/s43018-023-00588-x. Epub 2023 Jul 6.
The remarkable capacity of immunotherapies to induce durable regression in some patients with metastatic cancer relies heavily on T cell recognition of tumor-presented antigens. As checkpoint-blockade therapy has limited efficacy, tumor antigens have the potential to be exploited for complementary treatments, many of which are already in clinical trials. The surge of interest in this topic has led to the expansion of the tumor antigen landscape with the emergence of new antigen categories. Nonetheless, how different antigens compare in their ability to elicit efficient and safe clinical responses remains largely unknown. Here, we review known cancer peptide antigens, their attributes and the relevant clinical data and discuss future directions.
免疫疗法能够诱导部分转移性癌症患者的持久消退，这主要依赖于 T 细胞识别肿瘤呈递的抗原。由于检查点阻断疗法的疗效有限，肿瘤抗原具有被开发用于补充治疗的潜力，其中许多已经在临床试验中。人们对这一主题的兴趣激增，导致肿瘤抗原图谱的扩展，出现了新的抗原类别。尽管如此，不同抗原在引发有效和安全的临床反应方面的能力如何，在很大程度上仍然未知。在这里，我们回顾了已知的癌症肽抗原、它们的特性以及相关的临床数据，并讨论了未来的方向。
